Navigation Links
Bionovo Announces Publication of Data on Active Compound and Mechanism of Action for Its Preclinical Cancer Treatment, BN108

EMERYVILLE, Calif., April 20 /PRNewswire-FirstCall/ -- Bionovo, Inc. (Nasdaq: BNVI) today announced the poster presentation of significant, new data on the nature of the active compound and mechanism of action for its preclinical cancer drug candidate, BN108. The presentation is being made at the 2009 conference of the American Association of Cancer Research (AACR) in Denver, today.

In summary, the study concludes the following:

  • BN108, an aqueous extract of Anemarrhena asphodeloides, selectively induces cell death in breast cancer cells and other tumor cells without having a toxic effect on normal cells.
  • Timosaponin AIII (TAIII) has been identified as an active compound from BN108 that is responsible for the selective activity of BN108 towards breast cancer cells.
  • BN108 and TAIII rapidly and selectively inhibited major pro-survival cellular pathways that are often over-active in breast cancer.

"Currently available treatments for advanced breast cancer patients have limited efficacy and are associated with severe toxicity. Significantly more effective, less toxic therapies are urgently needed. Our studies suggest that therapeutic strategies based on BN108 and TspA3 may achieve more efficacious and safer clinical outcomes for breast cancer patients," stated Emma Shtivelman, Ph.D., the director of cancer research at Bionovo.

"BN108 offers great potential for the treatment of cancer. It is a drug that targets cell survival mechanisms, but it does it only in cancer cells. We anticipate it will have little to no collateral toxicity as is observed with all current cancer chemotherapy," said Isaac Cohen, chairman and CEO of Bionovo, Inc. "Bionovo is looking forward to entering clinical testing with BN108. We believe the market opportunity for drugs that are safe, effective and do not compromise the cancer patient's quality of life is exciting."

Bionovo, Inc.

Bionovo, Inc. is a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, markets with significant unmet needs and billions in potential annual revenue. The company applies its expertise in the biology of menopause and cancer to design new drugs derived from botanical sources which have novel mechanisms of action. Based on the results of early and mid-stage clinical trials, Bionovo believes they have discovered new classes of drug candidates within their rich pipeline with the potential to be leaders in their markets. Bionovo is headquartered in Emeryville, California and is traded on the NASDAQ Capital Market under the symbol, "BNVI". For more information about Bionovo and its programs, visit:

Forward Looking Statements

This release contains certain forward-looking statements relating to the business of Bionovo, Inc. that can be identified by the use of forward-looking terminology such as "believes," "expects," or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties, including uncertainties relating to product development, efficacy and safety, regulatory actions or delays, the ability to obtain or maintain patent or other proprietary intellectual property protection, market acceptance, physician acceptance, third party reimbursement, future capital requirements, competition in general and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Certain of these risks and uncertainties are or will be described in greater detail in our filings with the Securities and Exchange Commission, which are available at Bionovo, Inc. is under no obligation (and expressly disclaims any such obligation) to update or alter its forward-looking statements whether as a result of new information, future events or otherwise.

SOURCE Bionovo, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Bionovo Announces 2008 Highlights and Year-End Financial Results
2. Bionovo Announces Publication of Positive Phase 2 Trial Results for Menerba(TM)
3. Bert W. OMalley, M.D., Recipient of the 2008 National Medal for Science, Joins Bionovos Scientific Advisory Board
4. Bionovo Publishes Discoveries in Predictable Tissue Selectivity for Selective Estrogen Receptor Modulators Platform
5. Bionovo to Present Recent Findings of BN107, its Anticancer Agent, at the 31st Annual San Antonio Breast Cancer Symposium
6. Bionovo to Present at the Piper Jaffray Healthcare Conference
7. Ethan Weiss, M.D., Joins Bionovos Scientific Advisory Board
8. Bionovo Reports Third Quarter 2008 Financial Results
9. Bionovo to Present at Merriman Curhan Fords Investor Summit 2008 on September 15th
10. Bionovo to Present at Canaccord Adams Global Growth Conference
11. Bionovo Reports Second Quarter 2008 Financial Results
Post Your Comments:
(Date:11/24/2015)... , November 24, 2015 , ... a European healthcare fund ... companies will work closely together in identifying European breakthrough technologies ... need. The collaboration is underpinned by a significant investment by ... is the first investment by Bristol-Myers Squibb in a European ...
(Date:11/23/2015)... THOUSAND OAKS, Calif., Nov. 23, 2015   Ceres, ... company, announced today financial results for the fiscal year ... its business. --> --> ... on commercializing forage and feed products with a better ... the company signed distribution agreements with several leading crop ...
(Date:11/23/2015)... GENEVA , November 23, 2015 ... to develop daclatasvir for 112 ... countries   --> --> ... licence for a hepatitis C medicine, signing an agreement with ... proven to help cure multiple genotypes of the HCV virus. ...
(Date:11/23/2015)... , Nov. 23, 2015 /PRNewswire/ ... firm to exclusively serve the stem ... its global strategic report, "Mesenchymal Stem ... November 2015, it presents 250 pages ... stem cell (MSC) industry. ...
Breaking Biology Technology:
(Date:11/19/2015)... MOUNTAIN VIEW, Calif. , Nov. 19, 2015 /PRNewswire/ ... authentication market, Frost & Sullivan recognizes BIO-key with the ... Strategy Leadership. Each year, Frost & Sullivan presents this ... comprehensive product line catering to the needs of the ... which the product line meets and expands on customer ...
(Date:11/17/2015)... 2015 Paris from 17 ... Paris from 17 th until 19 ... innovation leader, has invented the first combined scanner in the ... same scanning surface. Until now two different scanners were required: one ... capture both on the same surface. This innovation is ...
(Date:11/16/2015)... 16, 2015  Synaptics Inc. (NASDAQ: SYNA ... today announced expansion of its TDDI product portfolio ... controller and display driver integration (TDDI) solutions designed ... new TDDI products add to the previously-announced ... (WQHD resolution), and TD4322 (FHD resolution) solutions. All ...
Breaking Biology News(10 mins):